Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPI pharmacokinetic study of pembrolizumab and post-immunotherapy salvage chemotherapy
2026-526866-26-00Phase 4Authorised
- Sponsor
- Centre Antoine Lacassagne
- Start
- Sep 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) (3 cohorts), sponsored by Centre Antoine Lacassagne. Primary endpoint: Objective response rate at 3 months. Planned start Sep 2026; status: authorised.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2026-526866-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526866-26-00.